TWI855102B - 細胞的分化狀態的評價方法、自富潛能幹細胞製造視網膜色素上皮細胞的方法、胚胎幹細胞製造視網膜色素上皮細胞的方法 - Google Patents
細胞的分化狀態的評價方法、自富潛能幹細胞製造視網膜色素上皮細胞的方法、胚胎幹細胞製造視網膜色素上皮細胞的方法 Download PDFInfo
- Publication number
- TWI855102B TWI855102B TW109121789A TW109121789A TWI855102B TW I855102 B TWI855102 B TW I855102B TW 109121789 A TW109121789 A TW 109121789A TW 109121789 A TW109121789 A TW 109121789A TW I855102 B TWI855102 B TW I855102B
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- stem cells
- amount
- indicator substance
- retinal pigment
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 310
- 230000004069 differentiation Effects 0.000 title claims abstract description 121
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 116
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 74
- 210000001671 embryonic stem cell Anatomy 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000000126 substance Substances 0.000 claims description 142
- 239000012228 culture supernatant Substances 0.000 claims description 98
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 65
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 65
- 229960003104 ornithine Drugs 0.000 claims description 65
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 65
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 64
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 63
- 229960002173 citrulline Drugs 0.000 claims description 63
- 235000013477 citrulline Nutrition 0.000 claims description 63
- 230000024245 cell differentiation Effects 0.000 claims description 34
- 230000008859 change Effects 0.000 claims description 29
- 239000001963 growth medium Substances 0.000 claims description 27
- 230000036962 time dependent Effects 0.000 claims description 27
- 230000004663 cell proliferation Effects 0.000 claims description 25
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 24
- 230000006698 induction Effects 0.000 claims description 23
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 claims description 20
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 18
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 16
- 230000002123 temporal effect Effects 0.000 claims description 16
- 108010024636 Glutathione Proteins 0.000 claims description 12
- 229960003180 glutathione Drugs 0.000 claims description 12
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 11
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 11
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 11
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 9
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 9
- 229930010555 Inosine Natural products 0.000 claims description 9
- 229960005305 adenosine Drugs 0.000 claims description 9
- 229960003786 inosine Drugs 0.000 claims description 9
- XJLSEXAGTJCILF-UHFFFAOYSA-N nipecotic acid Chemical compound OC(=O)C1CCCNC1 XJLSEXAGTJCILF-UHFFFAOYSA-N 0.000 claims description 9
- 239000005700 Putrescine Substances 0.000 claims description 8
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 claims description 4
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- 229960002433 cysteine Drugs 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 abstract description 9
- 239000002609 medium Substances 0.000 description 41
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 36
- 230000019612 pigmentation Effects 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 238000012258 culturing Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 206010064930 age-related macular degeneration Diseases 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 208000002780 macular degeneration Diseases 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102100022794 Bestrophin-1 Human genes 0.000 description 3
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 3
- 101001078886 Homo sapiens Retinaldehyde-binding protein 1 Proteins 0.000 description 3
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 3
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 3
- 102000002717 c-Mer Tyrosine Kinase Human genes 0.000 description 3
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102100030636 Homeobox protein OTX1 Human genes 0.000 description 2
- 102100030634 Homeobox protein OTX2 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000584392 Homo sapiens Homeobox protein OTX1 Proteins 0.000 description 2
- 101000584400 Homo sapiens Homeobox protein OTX2 Proteins 0.000 description 2
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 2
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 2
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001058 brown pigment Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- -1 isopropyl apple acid Chemical compound 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 101150111214 lin-28 gene Proteins 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/JP2019/028556 | 2019-07-19 | ||
| PCT/JP2019/028556 WO2021014515A1 (ja) | 2019-07-19 | 2019-07-19 | 細胞の分化状態の評価方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202117019A TW202117019A (zh) | 2021-05-01 |
| TWI855102B true TWI855102B (zh) | 2024-09-11 |
Family
ID=74193489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109121789A TWI855102B (zh) | 2019-07-19 | 2020-06-29 | 細胞的分化狀態的評價方法、自富潛能幹細胞製造視網膜色素上皮細胞的方法、胚胎幹細胞製造視網膜色素上皮細胞的方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220260580A1 (https=) |
| EP (1) | EP4001425A4 (https=) |
| JP (1) | JP7344421B2 (https=) |
| CN (1) | CN114450418A (https=) |
| TW (1) | TWI855102B (https=) |
| WO (1) | WO2021014515A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114846151A (zh) * | 2020-01-17 | 2022-08-02 | 株式会社日立高新技术 | 细胞分化状态的评价方法以及细胞培养系统 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017068727A1 (ja) * | 2015-10-23 | 2017-04-27 | 株式会社島津製作所 | 細胞の分化状態の評価方法 |
| TW201823451A (zh) * | 2013-12-11 | 2018-07-01 | 英商輝瑞有限公司 | 產製視網膜色素上皮細胞之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048999B2 (en) | 2005-12-13 | 2011-11-01 | Kyoto University | Nuclear reprogramming factor |
| DK2209888T3 (da) * | 2007-10-12 | 2020-01-20 | Astellas Inst For Regenerative Medicine | Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler |
| WO2012056997A1 (ja) * | 2010-10-28 | 2012-05-03 | 国立大学法人熊本大学 | 多能性幹細胞の分化誘導効率を改善するための方法及び培地 |
| KR101357851B1 (ko) * | 2011-11-02 | 2014-02-06 | 제일약품주식회사 | 낭성구조물로부터 망막색소상피세포의 분화를 유도하는 방법 |
| US10519422B2 (en) * | 2012-02-29 | 2019-12-31 | Riken | Method of producing human retinal pigment epithelial cells |
| KR102254082B1 (ko) | 2012-08-24 | 2021-05-18 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | 망막 색소 상피 세포 시트의 제조 방법 |
| US11022600B2 (en) * | 2014-05-01 | 2021-06-01 | Shimadzu Corporation | Method for assessing state of differentiation of cells |
| SG11201801770VA (en) * | 2015-09-08 | 2018-04-27 | Sumitomo Dainippon Pharma Co Ltd | Method for producing retinal pigment epithelial cells |
| CN106609256B (zh) * | 2015-10-22 | 2020-04-07 | 同济大学 | 体外诱导人胚胎干细胞分化为视网膜色素上皮细胞的方法 |
-
2019
- 2019-07-19 WO PCT/JP2019/028556 patent/WO2021014515A1/ja not_active Ceased
- 2019-07-19 US US17/628,023 patent/US20220260580A1/en active Pending
- 2019-07-19 JP JP2021534873A patent/JP7344421B2/ja active Active
- 2019-07-19 CN CN201980098491.9A patent/CN114450418A/zh active Pending
- 2019-07-19 EP EP19938680.6A patent/EP4001425A4/en active Pending
-
2020
- 2020-06-29 TW TW109121789A patent/TWI855102B/zh active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201823451A (zh) * | 2013-12-11 | 2018-07-01 | 英商輝瑞有限公司 | 產製視網膜色素上皮細胞之方法 |
| WO2017068727A1 (ja) * | 2015-10-23 | 2017-04-27 | 株式会社島津製作所 | 細胞の分化状態の評価方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021014515A1 (ja) | 2021-01-28 |
| EP4001425A1 (en) | 2022-05-25 |
| EP4001425A4 (en) | 2023-04-19 |
| TW202117019A (zh) | 2021-05-01 |
| JPWO2021014515A1 (https=) | 2021-01-28 |
| CN114450418A (zh) | 2022-05-06 |
| JP7344421B2 (ja) | 2023-09-14 |
| US20220260580A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220333069A1 (en) | Three dimensional heterogeneously differentiated tissue culture | |
| Tang et al. | Long-term culture of purified postnatal oligodendrocyte precursor cells: evidence for an intrinsic maturation program that plays out over months | |
| EP3787649B1 (en) | Diagnostic and drug screening for molecular signatures of early onset sporadic parkinson's disease | |
| Takata et al. | Lactate-dependent transcriptional regulation controls mammalian eye morphogenesis | |
| WO2019195800A1 (en) | Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells | |
| US20240150710A1 (en) | Assembled three-dimensional cultures of human neurons and glia and their use | |
| Young et al. | Ion channels and ionotropic receptors in human embryonic stem cell derived neural progenitors | |
| Prithviraj et al. | Differential regulation of dendrite complexity by AMPA receptor subunits GluR1 and GluR2 in motor neurons | |
| TWI855102B (zh) | 細胞的分化狀態的評價方法、自富潛能幹細胞製造視網膜色素上皮細胞的方法、胚胎幹細胞製造視網膜色素上皮細胞的方法 | |
| Béchade et al. | Nitric oxide regulates astrocyte maturation in the hippocampus: involvement of NOS2 | |
| Fagerlund et al. | Microglia orchestrate neuronal activity in brain organoids | |
| JP7790973B2 (ja) | パーキンソン病のための自家細胞置換療法 | |
| Puschmann et al. | Species differences in reactivity of mouse and rat astrocytes in vitro | |
| EP2739972B1 (en) | Method of identifying agents that affect maturation, survival and myelination | |
| JP2021191244A (ja) | 多能性幹細胞及びその利用、神経変性疾患の治療薬のスクリーニング方法、並びに、神経変性疾患の治療薬 | |
| Díaz et al. | TNF⍺-driven Aβ aggregation, synaptic dysfunction and hypermetabolism in human iPSC-derived cortical neurons | |
| US20240158745A1 (en) | Methods of generating oligodendrocyte progenitor cells and use thereof | |
| WO2025165614A1 (en) | Human sensory ascending pathway in assembloids derived from human pluripotent stem cells | |
| Mossink et al. | Cumulative contribution of EHMT1-deficient astrocytes to neuronal network dysfunction in Kleefstra syndrome | |
| Dirkx et al. | Unperturbed dye-based imaging of spontaneous synchronized calcium activity in iPSC-derived neuronal cultures | |
| McCready | Hyperconnectivity of iPSC-derived SHANK2 Neurons and Networks is Rescued by mGluR5 Agonism in an in vitro Model of Autism Spectrum Disorder | |
| KR20220121692A (ko) | 헌팅턴병 세포 모델 및 이를 이용한 헌팅턴병 스크리닝 모델 | |
| CN117625769A (zh) | Ssh2在诊断或预测雄性生育缺陷中的应用 | |
| Honsa | Neurogeneze a gliogeneze v dospělém mozku po ischemickém poškození | |
| Pusey | Effects of ectopic expression of the L1CAM long ectodomain in astrotypic human neural progenitor cells on motility, proliferation and differentiation |